Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2019 Jul 20;15(3):390–399. doi: 10.1007/s11481-019-09864-z

Figure 2. Knockdown of lincRNA-Cox2 reverses LPS-induced microglial proliferation.

Figure 2.

(A) Mouse primary microglial cells were transfected with lincRNA-Cox2-siRNA for 24 h, followed by exposure of cells to LPS (20ng/mL) for an additional 24 h and to BrdU incorporation for 30 min, and subsequently fixed, stained with anti-Iba-1, and anti-BrdU antibodies, and analyzed by confocal microscopy. (B) Mouse primary microglial cells were transfected with lincRNA-Cox2-siRNA for 24 h, followed by exposure of cells to LPS for an additional 24 h, and subsequently fixed, stained with anti-Iba-1, and anti-Ki67 antibodies, and analyzed by confocal microscopy. (C, D) Mouse primary microglial cells were transfected with lincRNA-Cox2-siRNA for 24 h, followed by exposure of cells to LPS for an additional 24 h. Cell proliferation was evaluated by (C) CyQuant assay and (D) Cell Counting Kit-8 (CCK-8) assay. Data are mean ± SEM of at least three independent experiments. Nonparametric Kruskal-Wallis one-way ANOVA followed by Dunn’s post hoc test was used to determine the statistical significance between multiple groups. *p < 0.05; * * *p < 0.001 versus control. #p < 0.05, # #p < 0.01 versus control-siRNA + LPS group. ns, not significant.